Alexander Azoy Sells 2,562 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,562 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the transaction, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,020,002.37. This trade represents a 6.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock traded up $0.40 on Monday, reaching $25.74. 1,450,131 shares of the stock were exchanged, compared to its average volume of 902,746. Arcus Biosciences, Inc. has a 1-year low of $7.91 and a 1-year high of $28.72. The company has a current ratio of 4.04, a quick ratio of 4.04 and a debt-to-equity ratio of 0.19. The business has a fifty day moving average price of $23.61 and a two-hundred day moving average price of $22.73. The firm has a market capitalization of $3.24 billion, a PE ratio of -8.10 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The firm had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.49 million. During the same quarter last year, the firm earned ($1.14) earnings per share. The company’s revenue was down 39.3% compared to the same quarter last year. As a group, research analysts anticipate that Arcus Biosciences, Inc. will post -3.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on RCUS shares. Wells Fargo & Company set a $23.00 target price on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a research report on Thursday, February 12th. Truist Financial initiated coverage on shares of Arcus Biosciences in a research report on Monday, May 18th. They set a “buy” rating and a $35.00 target price on the stock. Wall Street Zen downgraded shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Wedbush upped their price target on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Finally, Morgan Stanley upped their price target on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.89.

Institutional Trading of Arcus Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Hantz Financial Services Inc. lifted its holdings in shares of Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares in the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after buying an additional 2,845 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in shares of Arcus Biosciences during the fourth quarter valued at approximately $39,000. KBC Group NV purchased a new position in shares of Arcus Biosciences during the first quarter valued at approximately $50,000. Finally, Strs Ohio purchased a new position in shares of Arcus Biosciences during the first quarter valued at approximately $67,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.